320,723 Shares in Cerus Co. (NASDAQ:CERS) Acquired by River & Mercantile Asset Management LLP

River & Mercantile Asset Management LLP bought a new position in shares of Cerus Co. (NASDAQ:CERS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 320,723 shares of the biotechnology company’s stock, valued at approximately $1,802,000.

A number of other large investors have also recently made changes to their positions in the stock. SG Americas Securities LLC increased its holdings in shares of Cerus by 23.9% in the first quarter. SG Americas Securities LLC now owns 16,317 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 3,151 shares in the last quarter. Aperio Group LLC bought a new position in shares of Cerus in the second quarter valued at $27,000. Prudential Financial Inc. increased its holdings in shares of Cerus by 20.7% in the second quarter. Prudential Financial Inc. now owns 34,297 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 5,880 shares in the last quarter. Swiss National Bank increased its holdings in shares of Cerus by 3.0% in the second quarter. Swiss National Bank now owns 254,800 shares of the biotechnology company’s stock valued at $1,432,000 after buying an additional 7,500 shares in the last quarter. Finally, Raymond James Trust N.A. increased its holdings in shares of Cerus by 57.1% in the second quarter. Raymond James Trust N.A. now owns 22,000 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 8,000 shares in the last quarter. 72.94% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ CERS traded up $0.01 on Wednesday, hitting $4.46. 6,721 shares of the stock were exchanged, compared to its average volume of 864,617. Cerus Co. has a 52-week low of $4.41 and a 52-week high of $7.06. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.67 and a quick ratio of 2.33. The company has a market capitalization of $652.49 million, a price-to-earnings ratio of -10.14 and a beta of 1.64. The company’s 50-day moving average price is $5.14 and its two-hundred day moving average price is $5.44.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Cerus had a negative return on equity of 85.73% and a negative net margin of 98.69%. The firm had revenue of $18.20 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. Equities analysts predict that Cerus Co. will post -0.48 EPS for the current fiscal year.

In other news, Director Timothy B. Anderson sold 18,795 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $5.40, for a total transaction of $101,493.00. Following the transaction, the director now directly owns 177,649 shares in the company, valued at approximately $959,304.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Carol Moore sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $5.33, for a total transaction of $159,900.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,903 shares of company stock worth $394,513. Corporate insiders own 7.26% of the company’s stock.

CERS has been the topic of several research analyst reports. Stephens initiated coverage on shares of Cerus in a research report on Thursday, August 22nd. They set an “overweight” rating and a $8.00 price objective on the stock. ValuEngine upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. BidaskClub cut shares of Cerus from a “hold” rating to a “sell” rating in a research report on Friday, October 4th. Stifel Nicolaus initiated coverage on shares of Cerus in a research report on Tuesday, August 27th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $7.63.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: Google Finance

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.